4 Likes
It says 35% discontinuation rate. I don’t think there’s much difference between brilaroxazine and rexulti. Or any other partial agonist.
2 Likes
The total PANSS drop of -18.6 was higher than Rexulti or Abilify. In phase 2, the effect size .6 was similar to Resperdal.
The company may need financing, the stock is down
3 Likes